Vågen R, Götestam K G
Acta Psychiatr Scand. 1986 Nov;74(5):519-23. doi: 10.1111/j.1600-0447.1986.tb06277.x.
Seven psychotic inpatients (two women and five men) aged between 18 and 74 years, treated with neuroleptic and antiparkinson drugs, participated in a double-blind study with 1/3 DDD (Defined Daily Dose) of procyclidine, orphenadrine, or trihexyphenidyl hydrochloride against placebo. Euphoric effects were scored on a self-rating scale and extrapyramidal side-effects on the Simpson-Angus rating scale at drug administration and 1, 3 and 6 h thereafter. With regard to euphoric effect, there was a significant (P less than 0.02) difference between start and end point (0 and 6 h) for placebo but not for the active antiparkinson drugs. There was no significant difference in extrapyramidal side-effects. No preference of drug was found, and it was not possible to recognize the patient's own drug among the tested drugs. Side-effects from the antiparkinson drugs were also measured prior to the administration. Five patients did not return to their earlier antiparkinson drugs after the study.
7名年龄在18至74岁之间、正在接受抗精神病药物和抗帕金森病药物治疗的精神病住院患者参与了一项双盲研究，分别服用1/3限定日剂量（DDD）的丙环定、奥芬那君或盐酸苯海索，对照安慰剂。用药时以及用药后1小时、3小时和6小时，通过自评量表对欣快效应进行评分，并通过辛普森-安格斯评定量表对锥体外系副作用进行评分。关于欣快效应，安慰剂组用药起始和终点（0小时和6小时）之间存在显著差异（P<0.02），而活性抗帕金森病药物组则无此差异。锥体外系副作用方面无显著差异。未发现对药物有偏好，在受试药物中无法识别出患者服用的是其自身药物。在用药前也对抗帕金森病药物的副作用进行了测量。研究结束后，5名患者未恢复使用之前的抗帕金森病药物。
